Targeting of vasculature in cancer and other angiogenic diseases.
Kumar
S
S
Li
C
C
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D015703:Antigens, CD; D001172:Arthritis, Rheumatoid / Q000628:therapy; D003930:Diabetic Retinopathy / Q000628:therapy; D000071063:Endoglin; D004730:Endothelium, Vascular; D006801:Humans; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D009389:Neovascularization, Pathologic; D019636:Neurodegenerative Diseases / Q000628:therapy; D011565:Psoriasis / Q000628:therapy; D011956:Receptors, Cell Surface; D019030:Receptors, Vitronectin / Q000276:immunology; D012595:Scleroderma, Systemic / Q000628:therapy; D013792:Thalidomide / Q000627:therapeutic use; D019010:Vascular Cell Adhesion Molecule-1 / Q000276:immunology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D015703:Antigens, CD; C064206:ENG protein, human; D000071063:Endoglin; D011956:Receptors, Cell Surface; D019030:Receptors, Vitronectin; D019010:Vascular Cell Adhesion Molecule-1; D013792:Thalidomide